Waltham, Massachusetts, U.S., September 21, 2026
Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, announced that additional clinical results from its SIGNAL-AA Phase 2a trial of bempikibart in severe and very severe alopecia areata will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria. The company said the late-breaking presentations will include additional 36-week results and initial findings from a 16-week off-drug period evaluating whether hair regrowth responses persist after treatment. The presentations are scheduled for September 30, 2026, giving the scientific and dermatology communities an opportunity to review updated clinical and biomarker data from the investigational therapy.
Bempikibart Advances in Alopecia Areata Study
Bempikibart, also known as ADX-914, is a fully human anti-IL-7Rα antibody being developed by Q32 Bio for alopecia areata and potentially other autoimmune and inflammatory diseases. The therapy is designed to target the IL-7 and TSLP signaling pathways, which are involved in regulation of adaptive immune responses. By blocking IL-7Rα signaling, Q32 Bio is investigating whether bempikibart can help re-regulate abnormal immune activity associated with autoimmune disease. The ongoing SIGNAL-AA program is evaluating the treatment in patients with severe or very severe alopecia areata, a condition characterized by immune-mediated hair loss.
The upcoming late-breaking oral presentation will focus on hair regrowth durability and biomarker findings from Part B of SIGNAL-AA. Titled “Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata,” the presentation will include additional 36-week efficacy information as well as early findings from the period after patients stopped treatment. The presentation is scheduled for September 30 at 3:15 p.m. CEST in Hall A at the EADV Congress. A separate poster presentation will provide preliminary results from the open-label Phase 2a Part B study and is scheduled for the same day.
Updated Data to Highlight Treatment Durability
The 16-week off-drug period is an important component of the upcoming data presentation because it is intended to provide additional information about the durability of clinical responses after treatment is discontinued. For patients with severe alopecia areata, sustained hair regrowth and the potential duration of response are important considerations in evaluating new therapeutic approaches. Q32 Bio said the presentations will include both clinical and biomarker findings, potentially providing researchers with additional insight into the biological activity of bempikibart and its mechanism of action. However, the upcoming results should be viewed as clinical-development data from an investigational therapy rather than evidence of an approved treatment.
The EADV Congress presentation also represents an opportunity for Q32 Bio to share its IL-7Rα-targeted therapeutic approach with dermatology researchers and clinicians. The company is developing bempikibart not only for alopecia areata but also exploring its potential relevance across other autoimmune and inflammatory conditions in which T-cell-mediated immune activity plays a role. Q32 Bio states that approximately 700,000 people in the United States live with alopecia areata, highlighting the potential patient population affected by the condition. The company emphasized that bempikibart remains an investigational therapy, and its safety, efficacy, durability and regulatory potential continue to be evaluated through clinical development. The upcoming EADV presentations will therefore provide additional scientific information rather than representing a regulatory approval or established standard of care. Q32 Bio’s presentation of longer-term data from SIGNAL-AA Part B reflects the continuing evaluation of targeted biologic therapy for alopecia areata and the search for treatment approaches that may provide durable responses for patients with severe disease.
Source: Q32 Bio press release



